Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. provides comprehensive kidney care through a global dialysis and care-delivery network. Company news commonly covers quarterly operating results, revenue per treatment, patient care costs, reimbursement trends, share repurchases and investor conference participation.
Updates also address DaVita's value-based kidney care programs, coordinated care arrangements, and services that support patients across stages and settings of kidney disease, including home support, outpatient dialysis centers, hospitals, skilled nursing facilities and transplantation-related care.
DaVita Inc. (NYSE: DVA) has scheduled its second quarter 2025 earnings conference call for Tuesday, August 5, 2025, at 5:00 p.m. Eastern Time. The company will release its financial results after the market closes on the same day.
Investors can access the call through a webcast on DaVita's investor relations website or by dialing 877-918-6630 (US) or 517-308-9042 (International). Participants should provide the password "Earnings" when joining. A replay will be available on the company's website, but no telephone replay option will be provided.
DaVita Inc. (NYSE: DVA) has successfully upsized and priced its private offering of 6.750% senior notes due 2033 from $750 million to $1 billion. The notes were priced at 100.000% of their face value, yielding a 6.750% coupon. The offering is expected to close on May 23, 2025.
The company plans to use the proceeds to repay outstanding revolving credit facility borrowings, cover related costs and fees, and if funds remain, for general corporate purposes including stock repurchases, working capital, and capital expenditures. The notes were offered exclusively to qualified institutional buyers under Rule 144A and certain non-U.S. persons under Regulation S of the Securities Act.
DaVita Inc. (NYSE: DVA) has announced a private offering of $750 million senior notes due 2033. The company plans to use the proceeds to repay outstanding revolving credit facility borrowings and related interest, cover associated costs and fees, and if funds remain, for general corporate purposes including stock repurchases, working capital, and capital expenditures.
The notes are being offered exclusively to qualified institutional buyers under Rule 144A of the Securities Act and certain non-U.S. persons under Regulation S. The offering is not registered under the Securities Act or other jurisdictions' securities laws and cannot be sold in the United States without registration or an applicable exemption.
DaVita has announced its upcoming first quarter 2025 investor conference call, scheduled for Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company will release its Q1 results after the market closes on the same day.
Investors can participate through multiple channels:
- Webcast: Available via DaVita IR web page
- Domestic dial-in: 877-918-6630
- International dial-in: 517-308-9042
Participants must provide the password "Earnings" along with their name and company affiliation when calling in. While a replay will be accessible through the company's investor website (investors.davita.com), no telephone replay option will be available.
DaVita Inc. (NYSE: DVA) has announced its participation in the upcoming Barclays Global Healthcare Conference 2025. The company's CFO Joel Ackerman and Group VP of Investor Relations Nic Eliason will engage in a fireside chat with investors on March 11, 2025, at 9:00 a.m. EDT.
DaVita is a comprehensive kidney care provider with a 25-year track record in clinical quality and innovation. As of December 31, 2024, the company serves 281,100 patients across 3,166 outpatient dialysis centers, with 2,657 centers in the United States and 509 centers across 13 other countries. The company specializes in various aspects of kidney health, from disease progression management to transplantation support and home dialysis services.
DaVita Inc. (NYSE: DVA) reported strong financial results for Q4 2024. Consolidated revenues reached $3.295 billion for Q4 and $12.816 billion for the full year. The company achieved operating income of $565 million and adjusted operating income of $491 million in Q4, with full-year figures of $2.090 billion and $1.981 billion respectively.
Q4 diluted earnings per share was $3.09, with adjusted EPS at $2.24. Operating cash flow stood at $548 million with free cash flow of $281 million for the quarter. The company actively engaged in share repurchases, buying back 2.3 million shares at an average price of $156.46 per share in Q4.
DaVita provided dialysis services to approximately 281,100 patients across 3,166 outpatient centers globally, with 2,657 centers in the US and 509 centers across 13 other countries. However, U.S. dialysis treatments showed a per-day decrease of 1.4% compared to Q3 2024.
DaVita Inc. (NYSE: DVA) has announced its upcoming fourth quarter 2024 investor conference call, scheduled for Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company will release its financial results after the market closes on the same day.
The conference call will be accessible via webcast through DaVita's IR web page. Participants can join through the provided webcast link or by calling 877-918-6630 (domestic) or 517-308-9042 (international). Callers must provide the password 'Earnings' along with their name and company affiliation.
While a webcast replay will be available on investors.davita.com for those unable to attend the live call, there will be no telephone replay option available.